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a b s t r a c t
Supercritical ﬂuid impregnation was tested to prepare a new scaffold loaded with a bio-
active compound. Dexamethasone is used in osteogenic media to direct the differentia-
tion of stem cells towards the osteogenic lineage. Dexamethasone was impregnated in
chitosan scaffolds at different operating conditions, in order to optimize the impregnation
process. Pressure and temperature affect the carbon dioxide density and inﬂuence the
swelling of the polymer and the drug solubility in the ﬂuid phase, therefore these are
two important parameters that were studied in this work. Chitosan sponges prepared
by freeze drying were impregnated with the active compound at pressures from 8.0 up
to 14.0 MPa and temperatures from 35 up to 55 C. The effect of the impregnation contact
time (3 h and 6 h) was also evaluated. From the experiments performed we can conclude
that the yield of impregnation is lower when increasing pressure and temperature. The
contact time will mainly inﬂuence the amount of drug impregnated in the scaffold and
for higher contact times the impregnation yield is also higher. Scanning electron micros-
copy shows particles of dexamethasone in the bulk of the scaffold, which conﬁrms the
feasibility of the supercritical ﬂuid impregnation technology for the preparation of deliv-
ery devices. The loading capacity of the scaffolds was determined by spectroscopic anal-
ysis and the highest loading was achieved for the experiments performed at 8.0 MPa and
35 C. Furthermore, in vitro drug release studies were carried out and the results show
that dexamethasone was sustainably released. Supercritical ﬂuid impregnation proved
to be feasible for the preparation of a drug delivery system for bone tissue engineering
purposes.
 2008 Elsevier Ltd. All rights reserved.
1. Introduction
The emerging next generation of engineered tissues
relies on the development of loaded scaffolds containing
bioactive molecules in order to control the cellular func-
tion (e.g. growth or differentiation factors) or to act on
the surrounding tissues (e.g. drugs such as anti-inﬂamma-
tory agents or antibiotics) [1,2]. Hence, the strategy is to
mimic matrix and provide the necessary information or
signaling for cell attachment, proliferation and differentia-
tion to meet the requirement of dynamic reciprocity for
tissue engineering. This justiﬁes the importance of drug
delivery in tissue engineering applications [3,4].
Drug delivery systems, due to the wide range of materi-
als that can be processed, their various sizes and shapes as
well as different administration routes, are suitable for
many therapeutics applications. One ideal strategy in
tissue engineering is to enable the self-healing potential
of the patient to regenerate body tissue and organs [5,6].
This goal can be achieved if a bioactive scaffold is designed
in such a manner that at the same time it provides cells a
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support to grow and also induces their differentiation and
proliferation.
Small molecular weight drugs that control prolifera-
tion differentiation of cells can be incorporated into bio-
degradable scaffolds to induce cellular differentiation and
tissue remodeling. The scaffold plays, therefore an
important role not only as a physical support but also
in the cell proliferation and differentiation. Dexametha-
sone (chemical structure presented in Fig. 1) is an inter-
esting bioactive compound to be used in tissue
engineering applications. This drug is used in osteogenic
media to direct the differentiation of stem cells towards
the osteogenic lineage [7–9].
Chitosan is a cationic polymer derived from chitin
comprising copolymers of b(1?4)-glucosamine and
N-acetyl-D-glucosamine. Chitin is a natural-origin poly-
saccharide that can be found in crustacean shells. The
physicochemical and biological properties of chitosan
make it an excellent material for the preparation of drug
delivery systems and for the development of new
biomedical applications in many ﬁelds from skin to bone
or cartilage [10].
Chitosan has been processed in several forms to be used
in tissue engineering applications, namely, membranes
[11], particles [12], ﬁbers and 3D ﬁber meshes [13]. Chito-
san may also be used as a drug delivery carrier and various
studies have been reported in literature [14,15]. Chitosan
sponges and scaffolds are also described in literature as de-
liver systems able to carry active agents or biomolecules
and growth factors [16]. The preparation of these systems
normally envolves freeze-drying or lyophilising a chitosan
gel solution [17,18]. Supercritical ﬂuid impregnation of
bioactive molecules in chitosan derivatives with ﬂurbipro-
fen and timolol maleate has been successfully reported in
literature for ophthalmic drug delivery applications [19].
Additionally, thermo-responsive chitosan scaffolds pro-
cessed by means of a green technology are also described
in literature as smart partially-biodegradable scaffolds for
tissue engineering applications [20].
Conventional impregnation consists on the immersion a
polymeric matrix in a solution, which can be organic or
aqueous, where the drug(s) have been previously dis-
solved. However this method presents several disadvan-
tages, such as the use of toxic organic solvents, which
have to be removed and add a drying step to the drug de-
vice processing. Further, this drying step can include heat-
ing, which can degrade thermolabile substances.
The preparation of drug release products requires the
use of a mobile phase able to dissolve and carry the drug
component, that can also swell and stretch the polymer
matrix, facilitating the diffusion of the drug and increasing
the rate of impregnation.
Impregnation using supercritical ﬂuid technology has
proven to be feasible when the pharmaceutical compound
is soluble in carbon dioxide and the polymer can be swol-
len by the supercritical ﬂuid [21,22]. A high purity product,
free of residual solvents is obtained, since no organic sol-
vents are involved in the impregnation process. Supercrit-
ical ﬂuids, especially supercritical carbon dioxide (scCO2)
have been identiﬁed as prime candidates to develop alter-
native clean processes for the preparation of drug-loaded
polymeric matrixes [23]. Furthermore, the use of supercrit-
ical ﬂuids can take advantage of their high diffusivity in
polymers, in combination with the high solubility and
plasticizing action. Therefore, compressed CO2 can be used
as a solvent to carry the drug into biocompatible polymers
even if they are processed in complex shapes. Moreover,
when depressurisation occurs, the gas rapidly diffuses
out of the polymer, deplasticizing it and warranting the
complete removal of solvent, without exposing polymers
and drugs to high temperatures, which may degrade them
[24,25].
In this work the possibility of impregnating a chitosan
scaffold with dexamethasone was evaluated. The effect of
pressure, temperature and contact time was evaluated in
order to determine the best operating conditions for the
impregnation process. The loading capacity of the scaffolds
as well as the release proﬁles of the drug out of the delivery
device were evaluated and the results are presented.
2. Experimental procedure
2.1. Materials
Chitosan of medium molecular weight (degree of
deacetylation 85%), CAS [9012-76-4] was purchased from
Aldrich. Dexamethasone, CAS [50-02-2], (98% purity) and
phosphate buffer saline (PBS) were purchased from Sigma.
Acetic acid, CAS [64-19-7] (99.7% purity) was purchased
from Panreac. Distilled water was used. Carbon dioxide
(99.5%, industrial grade) was obtained from Air Liquide.
Chitosan was previously puriﬁed using a protocol de-
scribed elsewhere [26]. All the other products were used
with no further puriﬁcation.
2.2. Scaffold preparation
A solution of 4 wt% of chitosan in a diluted acetic acid
solution (2 wt% in water) was prepared. The solution was
poured into cylindrical moulds, which were froze at
80 C and lyophilised (Telstar-Cryodos –80 Spain) up to
4 days to completely remove the frozen solvent. Then,
the scaffolds were neutralized using a 0.1 m sodium
hydroxide solution and washed several times with distilled
water, as previously described elsewhere [27,28]. After this
procedure the samples were frozen at 80 C and once
again lyophilised.Fig. 1. Chemical structure of dexamethasone.
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2.3. Supercritical ﬂuid impregnation process
Supercritical ﬂuid impregnation was carried out in the
batch mode, as previous experiments show that this proce-
dure gives much higher yields of impregnation than the
continuous process [29,30]. The impregnation apparatus
is schematically presented in Fig. 2.
The equipment consists basically in a high pressure
reactor heated by means of a heating tape that maintains
the temperature within ±1 C. The temperature is mea-
sured by means of a thermocouple (WATLOW, 965 series).
CO2 was liqueﬁed through a cooling unit and compressed
to the operating pressure with a pump. The ﬂuid was pre-
heated to the desired temperature in a heat exchanger be-
fore entering the high pressure vessel. The pressure of the
system is measured with a pressure transducer (ASCO,
model PR711F). The previously processed scaffold and
the drug were loaded in the same vessel. Dexamethasone
was placed on the left hand side of the reactor and it was
separated from the polymeric matrixes with a cotton piece
in order to prevent contact of the two and thus, the con-
tamination of the surface of the scaffolds with the powder.
The vessel was set at the desired operational conditions
(T and p) and the impregnation took place for the pre-
determined period. At the end of this period, the system
was slowly depressurised.
2.4. Scaffold characterization
2.4.1. Scanning electron microscopy – SEM
Dexamethasone-loaded scaffolds were frozen in liquid
nitrogen and were fractured in order to observe a cross-
section of the matrix. The morphology of polymer samples
was analyzed and imaged by scanning electron microscopy
(SEM, Oxford Inca Energy 350) after gold coating.
2.4.2. Micro-computed tomography – micro CT
The inner structure and porosity of the scaffolds before
and after impregnation were evaluated by micro-comput-
erized tomography using a Scanco 20 equipment (Scanco
Medicals, Switzerland) with penetrative X-rays of 40 keV.
The X-ray scans were acquired in high-resolution mode
(39.39 lm). CT Vol (SkyScan, Belgium) was used to create
a 3D model of the scaffold.
2.5. Quantiﬁcation of drug loading
The dexamethasone-loaded scaffolds were weighed and
immersed in a PBS solution (0.01 M phosphate buffer,
0.0027 M potassium chloride and 0.137 M sodium chlo-
ride, pH 7.4). The solution was sonicated in order to extract
all the drug impregnated. In order to determine the
amount of solute, the resulting solutions were analyzed
by UV spectrophotometry in a UV–Vis (Shimazu UV
1601). Three loaded scaffolds impregnated under the same
conditions were analyzed. Dexamethasone absorbs in the
region of ultraviolet, with a maximum absorbance at
242 nm. Calibration was obtained by using of standard
samples with concentrations between (0.001 and
0.05) mg/mL.
2.6. In vitro release studies
The scaffolds impregnated with dexamethasone were
suspended in 10 mL of phosphate buffer saline solution
(PBS, 0.01 M phosphate buffer, 0.0027 M potassium chlo-
ride and 0.137 M sodium chloride, pH 7.4) stirred at
60 rpm at 37 C. Aliquots of 500 lL were withdrawn in pre-
determined time intervals (0.0833, 0.25, 0.5, 1, 2, 3, 7 and
8 h) and the same volume of fresh medium was added to
the solution in order to maintain the initial volume. Three
replicates were performed in order to calculate the stan-
dard deviation error. The samples analyzed by UV–Vis
spectroscopy at 242 nm (Shimazu UV 1601). Calculations
of the amount of drug released took into account the
replacement of aliquots with fresh medium.
2.7. Water uptake
The water uptake capability of the chitosan scaffolds
prepared by freeze-drying was determined using a simple
gravimetric method. Samples were weighed and immersed
10 mL of an isotonic solution at pH 7.4. The samples were
placed in a water bath at 37 C. After predetermined peri-
ods of time (1, 3, 5 and 7 h) the samples were weighed in
order to determine the water uptake of the scaffolds.
Water uptake was determined using the following
equation:
% water uptake ¼ ww wi
wi
 100 ð1Þ
where ww is the weight of the wet sample and wi is the
weight of the initial sample.
3. Results and discussion
In this study the possibility of preparing dexametha-
sone-loaded chitosan scaffolds with potential application
in tissue engineering using supercritical ﬂuid technology
was evaluated. Chitosan scaffolds were prepared by
freeze-drying after dissolution of the polymer in an acidic
solution. Due to the high viscosity of this solution and
the low solubility of dexamethasone in water, the conven-
tional impregnation process does not lead to a homoge-
neous drug delivery system. Thus, supercritical ﬂuid
impregnation seems an interesting alternative to the con-
ventional soaking method.
Supercritical ﬂuid impregnation experiments were per-
formed in a batch mode and different operational parame-
ters were evaluated. The design of the experiments was
P
TIC
CO2
liquid pump
HP vesse l
Fig. 2. Schematic diagram of the impregnation apparatus ((TIC) –
Temperature control, (P) – pressure transducer).
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developed in order to study the parameters that affect the
impregnation process. Experiments were carried out at
pressures ranging from 8.0 bar up to 14.0 MPa and temper-
atures from 35 up to 55 C. Also, two different contact
times during the impregnation process were studied. The
depressurisation rate was kept constant in all experiments,
as this is another variable that can inﬂuence the yield of
impregnation. Table 1 summarizes the experiments per-
formed and presents the percentage of drug impregnated
in each one of the experiments.
The chitosan scaffolds prepared by freeze-drying are
cylinders with an average diameter of 3.8 and 6.8 mm
height. They did not suffer morphological changes after
being subjected to high pressure carbon dioxide and this
was conﬁrmed by micro CT analysis. Chitosan scaffolds
prior to the impregnation process were analysed. Results
show that the scaffolds have a porosity of 87%, which
was the same value as observed for the scaffolds subjected
to high pressure. The 3D model of the scaffold is presented
in Fig. 3.
The resulting impregnated polymer scaffolds were cut
into sections and characterized by SEM analysis. An exam-
ple of the microstructure of an impregnated scaffold is pre-
sented in Fig. 4.
SEM analysis has shown that the drug is not deposited
on the surface of the matrix and it is found in the bulk of
the scaffold, in between the chitosan ‘‘leafs”. Furthermore,
no agglomeration of drug particles was found within the
structure, instead discrete particles were observed dis-
persed through the chitosan scaffold. The high diffusivity
of carbon dioxide in the polymer allows a homogeneous
distribution of the drug into the core of the scaffold, which
is one of the major advantages of the process. The diffusiv-
ity of carbon dioxide in a chitosan sphere was studied by
Weinstein and Papatolis [31] and it is reported to be in
the order of 107 m2/s, which is consistent with other re-
ported studies on the diffusion of carbon dioxide in poly-
meric matrixes.
Impregnation efﬁciency results from a complex mecha-
nism that involves interactions between the solute (dexa-
methasone), the carrier (carbon dioxide) and the matrix
(chitosan scaffold). The relative strength of all binary inter-
actions will contribute to the ﬁnal partitioning of the sol-
ute between the mobile phase and the solid. As an
example, a drug with a low solubility but exhibiting strong
interactions with the matrix could be impregnated in a
Table 1
Summary of the operational conditions of the experiments performed.
#Experiment Contact time (h) P (MPa) T (C) CO2 density (g/cm3)a % Impregnation
1 3 8.0 35 0.414 0.37
2 45 0.654 0.14
3 55 0.772 0.05
4 10.0 35 0.248 0.14
5 45 0.412 0.11
6 14.0 35 0.209 0
7 45 0.326 0.01
8 6 8.0 35 0.414 0.54
a Carbon dioxide density was calculated using the using Phase Equilibria program, developed in Professor Gerd Brunner’s department ‘‘Thermische
Verfahrenstechnik” at the University of Hamburg-Harburg.
Fig. 3. 3D model of the chitosan scaffold obtained by micro-CT analysis.
Fig. 4. SEM image a cross section of the chitosan scaffold loaded with
dexamethasone at 8.0 MPa and 55 C.
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large extent; conversely, a drug with a higher interaction
for the solvent compared to the solid will be poorly
impregnated.
In this work we deﬁne the yield of impregnation as the
relative quantity of drug in an impregnated scaffold, ex-
pressed as the ratio of drug weight/scaffold weight. The re-
sults presented are the average of at least three
experiments and the maximum standard deviation error
is 11%.
The effect of the impregnation contact time, pressure
and temperature are presented and discussed separately.
3.1. Contact time effect
The amount of drug impregnated can be tuned up to a
certain extent to the desired values by changing the
impregnation contact time. Increasing the impregnation
time, there is also an increase in the percentage of drug
impregnated in the polymeric matrix, as it would be ex-
pected (Fig. 5).
The supercritical ﬂuid impregnation process is gov-
erned by thermodynamic and mass transfer relationships
which are dependent, in a complex manner, on the carbon
dioxide pressure and operating temperature [32,33]. Pres-
sure and temperature not only affect the solubility of the
drug in the carbon dioxide but also inﬂuence the sorption
degree of the polymer, i.e., the amount of carbon dioxide
that is can be solubilized in the polymeric matrix. Three
different interactions, between polymer–CO2, drug–CO2
and drug–polymer are relevant for the understanding of
the mechanisms that govern this process. This is not al-
ways easy as the determination of the partition coefﬁcients
between the substances involved in the impregnation pro-
cess is difﬁcult to be calculated.
Gong and co-workers [34] have reported the impregna-
tion of indomethacin into chitosan matrixes using super-
critical ﬂuid technology. FTIR analysis of the matrixes has
shown that the aliphatic carbonyl group of indomethacin
interacts with the NH2 group of chitosan. Due to the low
drug loading of our samples FTIR results performed to
the impregnated scaffolds were inconclusive. However,
from the chemical structure of dexamethasone and chito-
san we can infer that possible hydrogen bonds are estab-
lished between the hydroxyl groups of the drug and the
amine groups of the polymer.
Kazarian and co-workers [25,35,36] distinguish two
mechanisms of impregnation assisted by supercritical ﬂu-
ids. The ﬁrst mechanism corresponds to a simple deposi-
tion of the compound when the ﬂuid leaves the swollen
matrix. In this case, the solute is solubilized in carbon diox-
ide and the polymer is exposed to this solution for a prede-
termined period followed by depressurization of the
system. When the system is depressurised, carbon dioxide
molecules quickly leave the polymer matrix, leaving the
solute trapped inside. As reported by Kazarian, this situa-
tion involves mostly solute with a relatively high solubility
in the ﬂuid and it is speciﬁc to impregnation carried out on
a matrix subjected to swelling upon exposure to the super-
critical ﬂuid. The second effect, not speciﬁc to supercritical
ﬂuids, corresponds to chemical interactions (like van der
Waals interactions) between the solute and the matrix,
that would favour the preferential partitioning of the sol-
ute with the polymer phase. According to our results and
for the particular case presented in this work, we believe
the second mechanism described is the one controlling
the impregnation process.
3.2. Pressure effect
The effect of pressure on the impregnation yield was
studied for different temperatures. In Fig. 6a, this effect is
shown.
Comparing isotherms of the experiments performed at
different pressures we can conclude that higher pressures
lead to lower impregnation yields.
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The effect of pressure is intimately related with the
sorption degree of the polymer in the presence of carbon
dioxide. Weinstein and Papatolis [31] report the sorption
of supercritical carbon dioxide in chitosan spheres for dif-
ferent operating conditions. According to this study, the
solubility of CO2 in the polymer increased as the operating
density and temperature increased. The work presented
can be extrapolated to our scaffolds and we can assume
that chitosan is able to dissolve carbon dioxide and swell
in the presence of this solvent. A pressure increase leads
to an increase in sorption degree of the polymer, for a given
temperature. Furthermore, the maximum sorption degree
is achieved after approximately 3 h of exposure, which
was the time set for the impregnation experiments. We
can then conclude that the effect of pressure on the
impregnation yield represents also the trend of the yield
of impregnation versus the sorption degree of the polymer.
Lower sorption degrees, therefore lower swelling of the
matrix will favour the interaction between dexamethasone
and the polymeric matrix leading to a higher yield of
impregnation. From the results obtained we can then con-
clude that higher impregnation yields are achieved at low-
er operational pressures.
Moreover, the pressure also affects the drug solubility
in carbon dioxide. For an isothermal pressure increase,
the solubility of the drug in the supercritical ﬂuid in-
creases. This can be easily explained in physical terms.
Density rises with increasing pressure, which means that
the intermolecular mean distance of the molecules de-
creases and the speciﬁc interactions between the solute
and the solvent increase, leading to a higher solubility. As
a consequence, the partition coefﬁcient of the drug to-
wards the polymeric matrix decreases and lower yields
of impregnation are achieved for the experiments per-
formed at higher pressures.
3.3. Temperature and density effect
The temperature plays two different roles regarding its
effect on the impregnation process. Whereas the solubility
of the drug increases with increasing temperature, after
the crossover region, the sorption degree of the polymer
is lower for higher temperatures.
In the case of the drug solubility, temperature inﬂu-
ences not only solid–vapour pressure but also solvent den-
sity and intermolecular interactions in the ﬂuid phase [37].
Regarding the sorption of the polymeric matrix, it has been
demonstrated that carbon dioxide interacts with the poly-
mer most probably through Lewis acid–base interactions
[38,39]. These interactions have an exothermic nature,
which might explain the fact that the solubility of carbon
dioxide in the polymer matrix decreases with increasing
temperature [40].
From the experiments carried out in this work we can
conclude that the impregnation yield decreases for an iso-
baric increase in temperature (Fig. 6b).
Higher densities (or higher temperatures) favour the
interactions between dexamethasone and carbon dioxide
and are detrimental to the bonding forces between the sol-
ute and the matrix, therefore at higher temperatures the
impregnation yield is lower [41,42].
The results obtained agree with the literature data
available for this kind of impregnation process and demon-
strate that although the solubility of the drug in the super-
critical solvent might not be very high, it does not
compromise the impregnation process. In the same way,
the sorption degree of the polymer should not be very large
otherwise the interactions between the solute and the ma-
trix are not promoted resulting in a poorly impregnated
polymer.
In the case of impregnation of chitosan scaffolds with
dexamethasone, and for the operating conditions tested
the higher impregnation yield was achieved for scaffolds
prepared at 8.0 MPa and 35 C, i.e., lower pressures and
temperatures.
3.4. Drug release proﬁle
The drug release proﬁle was evaluated for sample 2 pre-
pared at 80 bar and 45 C and it is presented in Fig. 7. In
this ﬁgure it is shown the amount of drug released as well
as the concentration of drug in solution.
Chitosan is a hydrophilic polymer and therefore has a
very high water uptake capability. We evaluated the water
uptake of the scaffolds prepared by freeze-drying in order
to have a better understanding on the mechanism of drug
release from these devices (Fig. 8).
The macroscopic observation of the chitosan scaffolds
allows us to conclude that chitosan is also a highly swella-
ble polymer. The diffusion of water into the polymeric ma-
trix facilitates the diffusion of the drug out of the
polymeric matrix into the physiological solution and there-
fore nearly 90% of the drug is released after 2 h.
Chitosan scaffolds are shown to be suitable as con-
trolled release devices able to incorporate and release ac-
tive molecules. The impregnation of dexamethasone has
two main purposes as it is not only a steroidal anti-inﬂam-
matory agent, but it also induces effectively differentiation
of bone marrow stem cells towards osteoblastic lineage.
For tissue engineering of bone from stem cells, medium
composition can guide differentiation along the osteogenic
lineage. Glucocorticoids, such as dexamethasone, are
added routinely in osteogenic medium as they show to
have stimulatory effects on skeletal cells. It has also been
suggested that the exposure of stem cells to dexametha-
sone may be effective in inducing and maintaining the
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Fig. 7. Dexamethasone release (h) and concentration of dexamethasone
in solution () from the scaffold prepared at 8.0 MPa and 45 C.
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osteoblastic phenotype [43]. Several studies in the litera-
ture report the in vitro osteogenic differentiation of puri-
ﬁed, culture-expanded human marrow stromal cells,
therefore, the preparation of a scaffold able to release an
active agent at a controlled rate, with the appropriate con-
centration is important.
We can conclude from the results obtained that
although the impregnation yield achieved using supercrit-
ical ﬂuid technology is apparently not very high, 0.0014 g
dexamethasone/g polymer, it still leads to concentrations
higher than the ones described for the preparation of oste-
ogenic medium (between 10 and 20 nM) [44].
4. Conclusions
Chitosan scaffolds were successfully impregnated with
dexamethasone. Different experimental conditions were
tested and the results obtained suggest that the best
impregnating conditions for this system are those involv-
ing low temperatures and pressures (8.0 MPa and 35 C),
which at the same time correspond to a lower solubility
of the drug in the supercritical ﬂuid and a low swelling
of the polymeric matrix.
Impregnation efﬁciency results from a complex mecha-
nism that involves interactions between the solute, the
carrier and the matrix. The relative strength of all binary
interactions will contribute to the ﬁnal partitioning of the
solute between the mobile phase and the solid. In the case
of the polymer and drug studied in this work, results sug-
gest that the interactions between the drug and the ﬂuid
phase are stronger than the ones of the drug to the poly-
meric matrix. From the chemical structure of the sub-
stances involved we can infer that hydrogen bonds can
be established between the hydroxyl groups of dexameth-
asone and the amine groups of chitosan. Therefore, lower
solvent densities favour the impregnation process.
The release of dexamethasone from chitosan scaffolds
presented a sustained proﬁle and we can conclude that
although the yield of impregnation using supercritical ﬂuid
technology is not very high it leads to drug concentrations
appropriate for applications in tissue engineering.
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